ECRM Generics: REPORTERS Notebook

February 2010
Drug Store News;2/16/2010, Vol. 32 Issue 2, p28
Trade Publication
The article offers news briefs related to the pharmaceutical industry in the U.S. including the approval of the Food and Drug Administration (FDA) on Ampyra extended-release tablets from Acorda Therapeutics, the launch of Sandoz of a generic version for schizophrenia and bipolar disorder drug and the introduction of Teva Pharmaceutical Industries of a generic treatment for eye relieving pressure.


Related Articles

  • Productivity Perspectives. Parker, Kevin // Processing (08968659);Apr2014, Vol. 27 Issue 4, p4 

    The author comments on drug quality and serialization in the U.S. pharmaceutical industry.

  • The Findings and Wider Impact of the EU Pharmaceutical Sector Inquiry. Priddis, Simon; Constantine, Simon // Antitrust Magazine;Spring2010, Vol. 24 Issue 2, p29 

    The article offers information on the Pharma Inquiry related to the European pharmaceutical sector conducted by the European Commission. The inquiry indicates that the Commission is committed to subjecting patent-related commercial practices undertaken by innovative pharmaceutical companies...

  • The 'rule of three' for fragment-based drug discovery: where are we now? Jhoti, Harren; Williams, Glyn; Rees, David C.; Murray, Christopher W. // Nature Reviews Drug Discovery;Aug2013, Vol. 12 Issue 8, p644 

    The article discusses the rule of three (RO3)3 in drug discovery in the U.S. The author mentions that the guidelines detail molecules' physicochemical properties associated with the fragment-based drug discovery (FBDD) screening. Moreover, they believed that FBDD would help in boosting the...

  • WHY YOU SHOULD BLAME WALL STREET FOR PHARMA'S STARTUP PROBLEM. Primack, Dan // Fortune;12/12/2011, Vol. 164 Issue 9, p82 

    The article discusses a threat to the development of new drugs in the U.S. Some drug companies including Pfizer are cutting their research-and-development budgets, preferring to buy small pharmaceutical startups rather than fund drug development themselves. However, venture-capital firms are...

  • New approval paths are needed, says Woodcock. Dickinson, James G. // Medical Marketing & Media;Jan2012, Vol. 47 Issue 1, p26 

    The article focuses on the remarks from U.S. Food and Drug Administration (FDA) director of drugs Janet Woodcock regarding her optimism on the pharmaceutical industry to produce better therapies.

  • Line Performance Optimization. Poland, Mike // Pharmaceutical Processing;May2012, Vol. 27 Issue 4, p36 

    The article discusses how line performance optimization (LPO) can solve issues that are plaguing the pharmaceutical manufacturing industry in the U.S. One method refers to developing a business case to ensure that the optimization effort is warranted from a business perspective. Another mentions...

  • Millennium CEO: pharma needs focus. Weinstein, Deborah // Medical Marketing & Media;May2012, Vol. 47 Issue 5, p19 

    The article reports on the views of Millennium Pharmaceuticals Inc.'s chief executive officer (CEO) Deborah Dunsire concerning the need for the U.S. pharmaceutical industry to pursue personalized medicine as blockbuster treatments are built on medications targeting small patient populations.

  • HARD OF (AD) HERING. Koroneos, George // Pharmaceutical Executive;Aug2008, Vol. 29 Issue 8, p42 

    The article focuses on the efforts by pharmaceutical companies in the U.S. in implementing technologies and programs to help patients adhere to their drug regimens. Reminder messaging, nurse services and disease-state compliance programs are at the top of the companies' list of compliance...

  • WEEK IN WASHINGTON.  // BioWorld Insight;8/12/2013, Vol. 21 Issue 33, p6 

    The article reports that the approval of the legislative bill H.R. 2985 on combination drugs by the U.S. House of Representatives can positively impact the U.S. drug makers and pharmaceutical firms and mentions that the bill can offer easy approval for manufacturing combination drugs.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics